A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells

Molecular Therapy

Volumn 16, Issue 4, 2008, Pages 765-772

  Steenblock, Erin R ^a   Fahmy, Tarek M ^a  

^a Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CYTOKINE RELEASE; ENCAPSULATION; EX VIVO STUDY; LYMPHOCYTE ACTIVATION; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PROTEIN BINDING; T LYMPHOCYTE;

EID: 41149095125     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.11     Document Type: Article

References (48)

1. Papadopoulos, EB, Ladanyi, M, Emanuel, D, Mackinnon, S, Boulad, F, Carabasi, MH et al. (1994). Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330: 1185-1191.
2. Savoldo, B, Heslop, HE and Rooney, CM (2000). The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma 39: 455-464.
3. + T cells. Adv Immunol 81 331-371.
4. + precursors in a thymus-independent process. J Immunol 172: 923-928.
5. Dudley, ME and Rosenberg, SA (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666-675.
6. Riddell, SR, Murata, M, Bryant, S, Warren, EH (2002). T-cell therapy of leukemia. Cancer Control 9: 114-122.
7. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173.
8. Oelke, M, Maus, MV, Didiano, D, June, CH, Mackensen, A and Schneck, JP (2003). Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9: 619-624.
9. Kim, JV, Latouche, JB, Riviere, I and Sadelain, M (2004). The ABCs of artificial antigen presentation. Nat Biotechnol 22: 403-410.
10. Hirano, N, Butler, MO, Xia, Z, Berezovskaya, A, Murray, AP, Ansen, S et al. (2006). Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 12 2967-2975.
11. Maus, MV, Thomas, AK, Leonard, DG, Allman, D, Addya, K, Schlienger, K et al. (2002). Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20: 143-148.
12. Mitchell, MS, Darrah, D, Yeung, D, Halpern, S, Wallace, A, Voland, J et al. (2002). Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20:1075-1086.
13. Jackson, MR, Song, ES, Yang, Y and Peterson, PA (1992). Empty and peptide-containing conformers at class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci USA 89: 12117-12121.
14. + T cells: Implications for tumor immunotherapy. Immunity 4 555-564.
15. Latouche, JB and Sadelain, M (2000). Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 18: 405-409.
16. Schoenberger, SP, Jonges, LE, Mooijaart, RJ, Hartgers, F, Toes, RE, Kast, WM et al. (1998). Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res 58: 3094-3100.
17. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272: 1939-1943.
18. Tham, EL, Jensen, PL and Mescher, MF (2001). Activation of antigen-specific T cells by artificial cell constructs having immobilized multimeric peptide-class I complexes and recombinant B7-Fc proteins. J Immunol Methods 249: 111-119.
19. Shalaby, WS, Yeh, H, Woo, E, Corbett, JT, Gray, H, June, CH et al. (2004). Absorbable microparticulate cation exchanger for immunotherapeutic delivery. J Biomed Mater Res B Appl Biomater 69: 173-182.
20. van Rensen, AJ, Wauben, MH, Grosfeld-Stulemeyer, MC, van Eden, W and Crommelin, DJ (1999). Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation. Pharm Res 16: 198-204.
21. Prakken, B, Wauben, M, Genini, D, Samodal, R, Barnett, J, Mendivil, A et al. (2000). Artificial antigen-presenting cells as a tool to exploit the immune "synapse". Nat Med 6: 1406-1410.
22. Thery, C, Zitvogel, L and Amigorena, S (2002). Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
23. Pardoll, DM (2002). Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2: 227-238.
24. Fyfe, G, Fisher, RI, Rosenberg, SA, Sznol, M, Parkinson, DR and Louie, AC (1995). Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696.
25. Schluns, KS and Lefrancois, L (2003). Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3: 269-279.
26. Riddell, SR (2007). Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematology Am Soc Hematol Educ Program 250-256.
27. Langer, R and Folkman, J (1976). Polymers for the sustained release of proteins and other macromolecules. Nature 263: 797-800.
28. Yamaguchi, K and Anderson, JM (1993). In vivo biocompatibility studies of medisorb(R) 65/35 D,L-lactide/glycolide copolymer microspheres. J Control Release 24: 81-93.
29. Fahmy, TM, Samstein, RM, Harness, CC and Saltzman, WM (2005). Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26: 5727-5736.
30. Mahoney, MJ and Saltzman, WM (2001). Transplantation of brain cells assembled around a programmable synthetic microenvironment. Nat Biotechnol 19: 934-939.
31. Jain, RA (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21: 2475-2490.
32. Hogquist, KA, Jameson, SC, Heath, WR, Howard, JL, Bevan, MJ and Carbone, FR (1994). T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
33. MacGlashan, DW Jr., Dembo, M and Goldstein, B (1985). Test of a theory relating to the cross-linking of IgE antibody on the surface of human basophils. J Immunol 135: 4129-4134.
34. Stone, JD, Cochran, JR and Stern, LJ (2001). T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. Biophys J 81: 2547-2557.
35. Fahmy, TM, Bieler, JG, Edidin, M and Schneck, JP (2001). Increased TCR avidity after T cell activation: A mechanism for sensing low-density antigen. Immunity 14: 135-143.
36. Mescher, MF (1992). Surface contact requirements for activation of cytotoxic T lymphocytes. J Immunol 149: 2402-2405.
37. + T cells. Eur J Immunol 27: 598-608.
38. Janeway, CA, Travers, P, Walport, M and Schlomchik, MJ (2005). Immunobiology: The Immune System in Health and Disease, 6 edn. Garland Science: New York.
39. van de Weert, M, Hennink, WE and Jiskoot, W (2000). Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17 1159-1167.
40. Cohen, S, Yoshioka, T, Lucarelli, M, Hwang, LH and Langer, R (1991). Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 8: 713-720.
41. Garlie, NK, LeFever, AV, Siebenlist, RE, Levine, BL, June, CH, Lum, LG (1999). T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother 22: 336-345.
42. + T cells. J Clin Invest 115: 1616-1626.
43. Oelke, M, Krueger, C, Giuntoli, RL 2nd and Schneck, JP (2005). Artificial antigen-presenting cells: Artificial solutions for real diseases. Trends Mol Med 11: 412-420.
44. Gopferich, A (1996). Mechanisms of polymer degradation and erosion. Biomaterials 17: 103-114.
45. Frank, A (2005). Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polymer International 54: 36-46.
46. Boyman, O, Kovar, M, Rubinstein, MP, Surh, CD and Sprent, J (2006). Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
47. Scheffold, A, Murphy, KM and Hofer, T (2007). Competition for cytokines: T(reg) cells take all. Nat Immunol 8: 1285-1287.
48. Schneck, JP, Slansky, JE, O'Herrin, SM and Greten, TF (2000). Monitoring antigen specific T-cell using MHC-Ig dimers. In: Current Protocols in Immunology John Wiley & Sons. pp. 17.12.11-17.12.17.